Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 13/20 | 0.89 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 4/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.43 |
| ▸ | SNCA | P37840 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | PLEC | Q15149 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8066 | 0.94 | APP (1.00) | APPCYP1A2ESR1ESR2SNCA | |
| SCHEMBL29456578 | 0.93 | APP (0.97) | APPCYP1A2ESR1ESR2SNCA | |
| Ammonia Solution, Strong SCHEMBL29419058 | 0.93 | APP (0.97) | APPCYP1A2ESR1ESR2SNCA | |
| SCHEMBL1095367 | 0.93 | APP (0.97) | APPCYP1A2ESR1ESR2SNCA | |
| SCHEMBL7113427 | 0.93 | APP (0.97) | APPCYP1A2ESR1ESR2SNCA | |
| Pyrophosphoric Acid SCHEMBL12479167 | 0.92 | APP (0.80) | APPCYP1A2ESR1ESR2SNCA | |
| Pyridine SCHEMBL591180 | 0.92 | APP (0.74) | APPCYP1A2ESR1ESR2SNCA | |
| Methoxymethane SCHEMBL2784008 | 0.89 | APP (0.89) | APPCYP1A2ESR1ESR2SNCA | |
| Phosphonic Acid SCHEMBL19693027 | 0.89 | APP (0.89) | APPCYP1A2ESR1ESR2SNCA | |
| Alcohol SCHEMBL6810203 | 0.88 | APP (0.86) | APPCYP1A2ESR1ESR2SNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 405 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023104380-A1 | SYNERGISTIC TRANSPORT OF LIPOPHILIC AND HYDROPHILIC ACTIVE SUBSTANCES IN NANOPARTICLES | Karlsruher Institut für Technologie (DE) | 2023-06-15 | — | — | WO | claimed |
| EP-4190312-A1 | SYNERGISTIC TRANSPORT OF LIPOPHILIC AND HYDROPHILIC ACTIVE AGENTS INTO NANOPARTICLES | Karlsruher Institut für Technologie (DE) | 2023-06-07 | — | — | EP | claimed |
| EP-1725676-B2 | MEASURING CONTAMINATION | MYCOMETER AS (DK) | 2016-07-27 | — | — | EP | claimed |
| EP-1725676-B1 | MEASURING CONTAMINATION | MYCOMETER AS (DK) | 2012-04-25 | — | — | EP | claimed |
| US-20110244510-A1 | Filtration method for detecting microbial contamination | MYCOMETER A/S (DK) | 2011-10-06 | — | — | US | claimed |
| US-7939285-B2 | Filtration method for detecting microbial contamination | MYCOMETER APS (DK) | 2011-05-10 | — | — | US | claimed |
| JP-4643262-B2 | — | — | 2011-03-02 | — | — | JP | claimed |
| JP-4643263-B2 | — | — | 2011-03-02 | — | — | JP | claimed |
| EP-1421213-B1 | LABELED NUCLEOSIDE POLYPHOSPHATES | GE HEALTHCARE BIO SCIENCES (US) | 2010-02-17 | — | — | EP | claimed |
| US-7625701-B2 | Triphosphate having gamma-phosphate with detectable group attached; detection using charge coupled device camera or photodiode; labeled nucleotide phosphate (e.g., gamma -NP-Dye) that on cleavage of phosphate detectable moiety (e.g., PPi-Dye) has different charge compared to intact nucleotide phosphate | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2009-12-01 | — | — | US | claimed |
| WO-2004020604-A2 | ALLELE SPECIFIC PRIMER EXTENSION | AMERSHAM BIOSCIENCES CORP (US) | 2004-03-11 | — | — | WO | claimed |
| US-20040048301-A1 | Allele specific primer extension | GLOBAL LIFE SCIENCES SOLUTIONS USA LLC | 2004-03-11 | — | — | US | claimed |
| US-20030162213-A1 | Terminal-phosphate-labeled nucleotides and methods of use | GLOBAL LIFE SCIENCES SOLUTIONS USA LLC | 2003-08-28 | — | — | US | claimed |
| US-20030124576-A1 | Such as (3-cyanocoumarinyl)dideoxyadenosine-5'-triphosphate which reacts with phosophatase to create detectable species (chemiluminescence, fluorescence); substrates for nucleic acid polymerases | GLOBAL LIFE SCIENCES SOLUTIONS USA LLC | 2003-07-03 | — | — | US | claimed |
| US-20030096253-A1 | Single nucleotide amplification and detection by polymerase | GLOBAL LIFE SCIENCES SOLUTIONS USA LLC | 2003-05-22 | — | — | US | claimed |
| US-20030077610-A1 | Terminal-phosphate-labeled nucleotides and methods of use | GLOBAL LIFE SCIENCES SOLUTIONS USA LLC | 2003-04-24 | — | — | US | claimed |
| WO-2003020984-A2 | TERMINAL-PHOSPHATE-LABELED NUCLEOTIDES AND METHODS OF USE | AMERSHAM BIOSCIENCES CORP (US) | 2003-03-13 | — | — | WO | claimed |
| WO-2003020891-A2 | SINGLE NUCLEOTIDE AMPLIFICATION AND DETECTION BY POLYMERASE | AMERSHAM BIOSCIENCES CORP (US) | 2003-03-13 | — | — | WO | claimed |
| WO-2003020734-A2 | LABELED NUCLEOSIDE POLYPHOSPHATES | AMERSHAM BIOSCIENCES CORP (US) | 2003-03-13 | — | — | WO | claimed |
| US-4719097-A | Phosphates of resorufin derivatives and compositions thereof for the determination of the activity of phosphatases | BOEHRINGER MANNHEIM GMBH (DE) | 1988-01-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030124576-A1 | Such as (3-cyanocoumarinyl)dideoxyadenosine-5'-triphosphate which reacts with phosophatase to create detectable species (chemiluminescence, fluorescence); substrates for nucleic acid polymerases | PNP, RNGTT, MTAP | APP 3481/4885CYP1A2 3369/4885ESR1 4741/4885 |
| US-20030077610-A1 | Terminal-phosphate-labeled nucleotides and methods of use | RNGTT, DNTT, PNP | APP 3307/4885CYP1A2 4004/4885ESR1 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.